Fresenius Injects $5.1 Billion into its U.S. Pharma Unit

Fresenius Medical Care AG & Co. KGaA (NYSE: FMS) has been a busy deal maker. In 2016, its subsidiary Fresenius Helios bought the Spanish hospital chain Quironsalud for $6.5 billion, its Renal Care division acquired the rights to a chronic kidney disease drug for up to $282 million, and then a German-based cardiovascular medical device company for an undisclosed price. The company also picked up dialysis clinics throughout India and New York State, and other drug licenses in the meantime. Now, it has turned its attention to strengthening Fresenius Kabi, its sterile injectable medicines subsidiary. Biosimilars are a fast-growing segment within the pharmaceutical market, and some of the... Read More »

Fresensius Helios Adds 43 Spanish Hospitals

Fresenius Helios (EXTRA: FRE.DE) was already the largest private hospital company in Europe, and now it’s grown even larger. On September 5, 2016, the company announced the acquisition of Quirónsalud, Spain’s largest private hospital operator, with 43 hospitals, 39 outpatient centers, and 300 occupational risk prevention centers.  Quirónsalud was created by the 2014 merger of IDC Salud and Grupo Hospitalario Quirón. Fresenius Helios, a division of Fresenius SE & Co. KGaA, vaulted to the top of the private European hospital market in September 2013, following the  its acquisition of 43 hospitals and 15 outpatient facilities in Germany, sold by Rhön Klinikum AG, for... Read More »